Synaptogenix Inc (SNPX)

[Doc328]

Yes they would pay. The "payment" is a tax incentive to spur on more clinical trials in Australia --- and it is working. If NTRP did a study in AU they would get the same incentive. Baby Pharma gets back 43.5% of expenses inccurred in Australia while Big Pharma would get 38% back. The incentive is not an endorsement of the drug, company or science. As with every study, they would need authorization from the TGA to proceed. The TGA is not psychic. If you put together a protocol for any drug for any indication that is reasonable and follows GCP they will approve, just as the EMA and FDA will. The TGA has authorized studies that fail including the amyloid MAb's. The tax incentive is great for small bio and a rebate is better at that stage than a tax offset from carryover losses.

Australia is riding a wave of R&D, thanks to generous government tax incentives, as well as the quality of contract research and speed of performing clinical trials.

The incentives provide businesses investing in eligible R&D, including clinical trials, with:

A 43.5% refundable R&D tax offset for a company with a total annual revenue of less than $20-million (Australian) and that incur a loss;



A 43.5% non-refundable R&D tax offset for companies with a total annual revenue of less than $20-million and that incur a profit;

And a 38% non-refundable R&D tax offset for companies with total annual revenue of more than $20-million, irrespective of profit or loss.